Daniela Slavin

Provided scientific and strategic leadership for global Phase I–III oncology trials, supporting execution from study start-up through clinical data readout and regulatory deliverables. Co-developed clinical program and study strategy, reviewed key clinical/regulatory documents, and partnered cross-functionally to ensure delivery within scope, timelines, and budget.

Supported global Phase I–III oncology clinical development workstreams from study start-up through data readout and reporting. Contributed to protocol optimization, clinical data review and query generation, safety signal/risk assessments, and regulatory interactions with global health authorities.

Led coordination and execution of 30+ oncology clinical trials, overseeing site operations, patient enrollment, and study conduct in compliance with GCP/ICH. Served as a primary liaison across investigators, sponsors, CROs, and patients, ensuring protocol compliance, patient safety, and accurate data collection/reporting.

Coordinated oncology clinical trial activities across multiple protocols, supporting enrollment, protocol compliance, patient safety, and accurate data collection/reporting. Trained and mentored site staff and contributed to process improvements to improve operational efficiency and study timelines.

Designed and executed high-throughput screening assays to support oncology drug discovery, including developing and miniaturizing assays for large-scale compound screening. Identified 120 lead compounds from a 2M compound library and implemented Proximity Ligation Assay technology for HTS applications.

Investigated signaling pathways and mechanisms of action for cytokine-based therapeutics, designing and executing experiments to support target validation. Identified DNA sequences differentiating compound activity between species and reduced time required for mechanism-of-action studies.

PhD in Chemical Sciences / Biochemistry from the National University of Córdoba.